ARO AAT

Drug Profile

ARO AAT

Alternative Names: ARO-AAT

Latest Information Update: 20 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arrowhead Pharmaceuticals
  • Class
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alpha 1-antitrypsin deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alpha 1-antitrypsin deficiency

Most Recent Events

  • 12 Mar 2018 Phase-I clinical trials in Alpha 1-antitrypsin deficiency (In volunteers) in New Zealand (SC)
  • 22 Feb 2018 The New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and local Ethics Committee approves CTA for a phase I trial of ARO AAT in Alpha 1-antitrypsin deficiency
  • 15 Feb 2018 ARO AAT receives Orphan Drug status for Alpha 1-antitrypsin deficiency in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top